Analyst Reco. Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:05 2024-04-23 pm EDT			5-day change	1st Jan Change
149.5 ^USD	+0.28%		+3.52%	-4.59%

Apr. 22	J&J: EU green light for Carvykti in multiple myeloma	CF
Apr. 22	Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	Apr. 22	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	Apr. 17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	Apr. 17	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	Apr. 16	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	Apr. 09	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	Apr. 05	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	Apr. 04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	Jan. 24	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	Jan. 24	MT
The market awaits the BCE meeting and earnings reports	Jan. 23
The start of a new bull market?	Jan. 22
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	Jan. 09	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	Jan. 03	MT
ANALYST RECOMMENDATIONS : Adobe, Airbnb, Netflix, Nike, Etsy...	Dec. 14
Wells Fargo Downgrades Johnson & Johnson to Equalweight From Overweight, Cuts Price Target to $163 From $170	Dec. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST